Eligibility for an opioid class action depends on who you are — a government entity, a hospital, or an individual — and which settlement you are trying to participate in. For individuals, the core requirement across most opioid settlements is proof that you were prescribed a specific opioid product and suffered injury, addiction, or death as a result. For state and local governments, eligibility has been broader, with 46 states participating in the landmark $26 billion national settlement reached in July 2021 with Johnson & Johnson, AmerisourceBergen, Cardinal Health, and McKesson. The opioid litigation landscape in 2025 and 2026 is not a single lawsuit but a web of overlapping settlements, bankruptcy proceedings, and personal injury trusts, each with its own eligibility criteria and deadlines.
The Purdue Pharma and Sackler family settlement alone set aside roughly $850 million for individual victims, but claimants must prove they were prescribed OxyContin specifically. The Mallinckrodt Opioid Personal Injury Trust has its own separate claim process. Total opioid settlement dollars tracked nationally now exceed $50 billion across all defendants combined, yet navigating which pot of money you qualify for — and when the deadline is — remains genuinely confusing.
Table of Contents
- Who Qualifies for an Opioid Class Action Settlement?
- What Are the Specific Requirements for the Purdue Pharma Settlement?
- How the Mallinckrodt Opioid Trust Handles Individual Claims
- Government vs. Individual Claims — Which Path Applies to You?
- Deadlines and Common Pitfalls That Disqualify Claimants
- The Role of Bellwether Trials and the MDL Process
- What Comes Next for Opioid Settlement Eligibility
- Frequently Asked Questions
Who Qualifies for an Opioid Class Action Settlement?
The answer depends heavily on the type of claimant. The national opioid settlements were designed primarily for government plaintiffs — states, counties, cities, towns, and tribal governments. These entities sued pharmaceutical manufacturers and distributors for the public costs of the opioid crisis: emergency room visits, addiction treatment programs, build care for children of addicted parents, and law enforcement expenses. Under the national settlement framework, at least 70% of all funding must be spent on opioid remediation efforts, with allocation split into 15% for a State Fund, 70% for Abatement Accounts, and 15% for a Subdivision Fund. Hospitals carved out their own lane.
Over 1,000 hospitals that treated patients with opioid use disorder filed suit and secured a combined $651 million in direct compensation settlements. All federally recognized tribes are also eligible to participate in tribal opioid settlements, regardless of whether the tribe independently filed an opioid lawsuit — a significant distinction, since many smaller tribes lacked the legal resources to initiate litigation on their own. For individuals, the path is narrower. you generally must show that you were prescribed an FDA-approved opioid and that you suffered injury or addiction as a direct result. The most common qualifying scenarios include developing addiction due to physician overprescribing, being a close family member of someone who died from an overdose (a wrongful death claim), or being a patient who was reassured by a doctor that the prescribed opioid was not addictive. Wrongful death cases tend to be the most viable individual claims, though addiction itself is recognized as a compensable injury.
What Are the Specific Requirements for the Purdue Pharma Settlement?
The $7.4 billion Purdue Pharma and Sackler family settlement is the highest-profile individual-facing opioid settlement to date. A federal bankruptcy judge formally approved it in November 2025, and all 55 eligible attorneys general — covering every state and U.S. territory — joined the agreement. But the fact that your state joined does not automatically mean you, as an individual, receive compensation. Of the $7.4 billion total, approximately $850 million is designated for individual victims, including children born with opioid withdrawal symptoms. The critical eligibility requirement here is specific: individuals must prove they were prescribed OxyContin.
Not opioids generally — OxyContin specifically, which is Purdue Pharma’s branded product. If you were prescribed a different opioid, such as hydrocodone or a generic oxycodone product made by another manufacturer, the Purdue settlement is not the right vehicle for your claim. However, if you do qualify, expected individual payouts are approximately $8,000 or $16,000 per person, depending on the duration of your prescription and the total number of qualifying claimants. Distribution to individual victims is expected to begin in 2026. The payment schedule from the Sackler family starts with $1.5 billion plus roughly $900 million from Purdue in the first payment in early 2026, followed by $500 million after one year, another $500 million after two years, and $400 million after three years. The staggered timeline means full payout will take years to complete.
How the Mallinckrodt Opioid Trust Handles Individual Claims
Mallinckrodt, a major generic opioid manufacturer, established a separate Opioid Personal Injury Trust through its own bankruptcy proceedings, and the eligibility requirements differ from the Purdue settlement in meaningful ways. The trust handles two distinct categories of claims: Non-NAS personal injury claims and NAS (Neonatal Abstinence Syndrome) claims. For Non-NAS claims, you must demonstrate two things: first, that you received a prescription for a Mallinckrodt opioid product (including off-label use), and second, that you were injured from using that Mallinckrodt opioid. This is product-specific — you need to connect your injury to a Mallinckrodt-manufactured drug, not just any opioid. For NAS claims, the requirement is different: any person diagnosed by a licensed medical provider with a medical, physical, cognitive, or emotional condition resulting from intrauterine exposure to opioids qualifies.
This covers children who were born with withdrawal symptoms because their mothers used opioids during pregnancy. The trust has received approximately 37,000 claims and processes them on a first-in, first-out basis. Most approved claims were expected to be paid by mid-2025. A critical warning: the filing deadline for Non-Future Non-NAS PI Claims was June 15, 2025, and all claims not filed by that date are permanently barred. NAS claims also had to be filed within three years of the Effective Date or by June 15, 2025. If you missed these deadlines, the Mallinckrodt trust is no longer an option regardless of the merits of your claim.
Government vs. Individual Claims — Which Path Applies to You?
Understanding the difference between government-level claims and individual personal injury claims is essential, because the two paths have almost nothing in common besides the underlying crisis. Government settlements are negotiated by attorneys general and local officials on behalf of the public. The money flows to state and local programs — treatment centers, naloxone distribution, drug courts, prevention education. You do not receive a personal check from these settlements, even though the funds theoretically benefit you as a resident. Individual claims, by contrast, go through personal injury trusts or direct litigation. The tradeoff is significant.
Government claims involve far larger sums of money — the $26 billion national settlement dwarfs any individual trust fund — but none of that money goes directly to people who were harmed. Individual trusts offer direct compensation, but the per-person amounts are modest. An expected $8,000 to $16,000 payout from the Purdue settlement, for instance, does not come close to covering the actual cost of addiction treatment, lost wages, or the devastation of losing a family member to an overdose. For someone weighing their options, the practical question is whether you have a viable individual claim at all. If you were prescribed OxyContin and can document it, the Purdue settlement’s individual victim fund may apply. If your opioid was manufactured by Mallinckrodt and you filed before the deadline, that trust was another avenue. For those whose situations do not fit neatly into an existing settlement, a separate personal injury lawsuit through the opioid MDL (multidistrict litigation) may still be possible, though these cases are complex and typically require attorney representation.
Deadlines and Common Pitfalls That Disqualify Claimants
The single biggest reason people lose eligibility for opioid compensation is missing a deadline. Opioid settlements operate on strict filing windows, and unlike some consumer class actions where late claims are occasionally accepted, bankruptcy-administered trusts generally enforce their cutoff dates without exception. The Mallinckrodt trust’s June 15, 2025 deadline is a case in point — if you did not file by that date, you are barred regardless of the severity of your injury. For government entities in the national settlement, the subdivision participation deadline was October 8, 2025, by which local governments had to execute their Subdivision Participation Form. Missing that window meant forfeiting the municipality’s share of settlement funds.
Beyond deadlines, the most common pitfall is lack of documentation. You need medical records showing the specific opioid you were prescribed, the prescribing physician, and the timeframe of use. Individuals who obtained opioids without a prescription, through diversion or illicit markets, generally do not qualify for settlement compensation — even though they may have suffered equally devastating consequences. This is a real limitation of the current settlement framework: it was built around the pharmaceutical supply chain, and eligibility is tied to that chain. People harmed by illicit fentanyl, for example, fall outside virtually all existing opioid settlements.
The Role of Bellwether Trials and the MDL Process
For claims that do not fit within an existing settlement, the opioid multidistrict litigation remains active. Eleven bellwether trials have been set so far in the opioid MDL, with plaintiff categories spanning states, Native American tribes, local governments, hospitals, and third-party payors such as insurance companies. These bellwether trials serve as test cases — their outcomes influence the settlement terms offered to similar plaintiffs.
In March 2025, the MDL court established a Qualified Settlement Fund framework to support ongoing tribal settlements, signaling that the litigation is still producing new avenues for compensation even years after the initial wave of settlements. For individuals considering joining the MDL process now, the practical reality is that you will almost certainly need an attorney, and the timeline from filing to resolution can stretch years. But for those with strong cases — particularly wrongful death claims — the MDL remains a viable path.
What Comes Next for Opioid Settlement Eligibility
The opioid settlement landscape is still evolving. With the Purdue Pharma settlement formally approved in November 2025 and individual payouts expected to begin flowing in 2026, we are entering the distribution phase for some of the largest settlements in American legal history. But new defendants continue to be added, and the MDL process is far from over.
The $50 billion-plus in total tracked settlement dollars represents an extraordinary sum, yet it remains a fraction of the estimated economic cost of the opioid crisis. For individuals and communities still dealing with the fallout, staying aware of new settlement opportunities and deadlines is the most practical step available. New trusts and settlement funds could emerge as additional defendants reach agreements, particularly among pharmacy chains and smaller manufacturers that have not yet resolved their litigation.
Frequently Asked Questions
Do I qualify for an opioid settlement if I was addicted to opioids but never had a prescription?
Generally, no. Existing opioid settlements and trusts require proof of a legitimate prescription from a licensed physician. Individuals who obtained opioids through non-prescription channels are typically excluded from current settlement frameworks, even if they suffered serious harm.
How much money will I receive from the Purdue Pharma settlement as an individual?
Expected individual payouts are approximately $8,000 or $16,000 per person, depending on the duration of your OxyContin prescription and the total number of qualifying claimants. Distribution is expected to begin in 2026.
Can I file an opioid claim if my family member died from an overdose?
Yes. Wrongful death claims are among the most viable individual opioid claims. Close family members of overdose victims may qualify, though you will typically need to show that the deceased was prescribed the opioid in question and that it contributed to their death.
Is it too late to file an opioid claim?
It depends on the specific settlement. The Mallinckrodt trust deadline of June 15, 2025 has passed, and claims not filed by then are barred. However, the opioid MDL is still active, and the Purdue settlement is still in its distribution phase. New settlements may create future filing opportunities.
Do tribal governments need to have filed a lawsuit to participate in opioid settlements?
No. All federally recognized tribes are eligible to participate in tribal opioid settlements regardless of whether they independently filed an opioid lawsuit.
Where does the government settlement money actually go?
Under the national opioid settlement, at least 70% of funding must be spent on opioid remediation efforts. The allocation breaks down to 15% for a State Fund, 70% for Abatement Accounts, and 15% for a Subdivision Fund. This money funds treatment programs, prevention efforts, and related public health initiatives — it does not go directly to individuals.
You Might Also Like
- What Happens to Leftover Money When Class Action Claims Are Low
- How to Prove Eligibility for a Class Action Without Original Receipts
- Can a Class Action Settlement Payment Affect Your Medicaid Eligibility